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ABSTRACT: A series of isatin Schiﬀ base derivatives were identiﬁed during in
silico screening of the small molecule library for novel activators of p53. The
compounds selected based on molecular docking results were further validated
by a high-content screening assay using U2OS human osteosarcoma cells with
an integrated EGFP-expressing p53-dependent reporter. The hit compounds
activated and stabilized p53, as shown by Western blotting, at higher rates than
the well-known positive control Nutlin-3. Thus, the p53-activating compounds
identiﬁed by this approach represent useful molecular probes for various cancer
studies.
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The p53 protein functions primarily as a sequence-speciﬁctranscription factor,1 and it drives the expression of a large
number of genes2 in response to various stimuli.3 The current
view is that p53, in addition to its crucial role in anticancer
responses,4 also plays a role in inﬂammation.5 The attenuation
of p53 activity (commonly caused by point mutations or
overexpression of its negative regulatory proteins) leads to
uncontrolled cell proliferation.
P53 has a wide network of protein−protein interactions6
(PPI), and some of the interacting proteins are key players in
the regulation of tumor growth.7 However, among the wide
variety of p53 PPIs, only several interacting proteins are directly
responsible for p53 activity and stability. Therefore, blunting
these critical p53-related PPIs has been shown to be a
successful strategy for cancer treatment.8
There are several pharmacological methods to stimulate p53
antitumor activity: (a) small molecules (SM) that cause
genotoxic stress (for example, doxorubicin);7 (b) reactivators
of mutant p53, which revert the p53 molecule to the wild-type
conformation;9 and (c) SM PPI inhibitors that block the
ubiquitin-mediated proteasomal degradation of p53.8 The latter
“class” of molecules seems to be the most promising as it
generally exhibits lower toxicity levels.
As mentioned above, p53 is subject to ubiquitin-dependent
degradation, and the principal p53-speciﬁc E3 ubiquitin ligase is
mouse double minute (MDM2) protein. Perhaps not
surprisingly, MDM2 is a major pharmacological target.
Importantly, unlike acetylation10 or methylation, MDM2-
dependent ubiquitination of p53 on several lysine residues in
its C-terminus signiﬁcantly destabilizes the protein.10 In recent
years, MDM2 has been recognized as the critical protein to
target for p53 stabilization.11
The p53 protein can be structurally divided into four
domains: the N-terminal region that includes two trans-
activation domains (TADs), the proline-rich region, the central
core DNA-binding domain, and the C-terminal tetramerization
and regulatory domain.12
The p53 TADs are the main interface for interaction with the
regulatory protein MDM2. The α-helical part of TAD1 (key
residues Phe19, Trp23, and Leu26) within the p53 protein
interacts with MDM2 by binding to its N-terminal hydrophobic
pocket. The p53-binding part of MDM2 is rigid, and its solved
structure is widely used in molecular docking studies.13
Most of the MDM2 inhibitors mimic the structure of the
TAD1 α-helix14 and hence form the same intermolecular
contacts with the hydrophobic MDM2 pocket as the original
p53. An alternative concept of stapled peptides was shown to
be a successful strategy in attempts to inhibit MDM2.15 Nutlin-
3 is the most studied SM inhibitor of the MDM2−p53
interaction; it has been examined through in vitro and in vivo16
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experiments. Several NMR17 and X-ray18 studies have speciﬁed
the binding pose and details of its interactions with MDM2.
Nutlin-3 was able to reactivate p53 in a nongenotoxic manner
in clinical trials.19 To date, many Nutlin derivatives with higher
aﬃnities for MDM2 have been developed. Isoindolinones are
derivatives of one promising “class” of inhibitors showing in
vivo and in vitro activity.20 Benzylideneindoline-2-ones have
recently been presented as MDM2-p53 PPI inhibitors that
exhibit in cellulo activity.21 More detailed information about PPI
inhibitors is presented in the recently published review.22
The isatin (1H-indole-2,3-dione) scaﬀold (benzylideneindo-
line-2-one analogue) is widely used in drug discovery studies.23
N-Substituted isatin piperazine derivatives have been reported
as selective inhibitors for aldehyde dehydrogenases in in vitro
assays,24 and the crystal structures of protein−ligand complexes
have validated the mechanism of their action. Piperidine
analogues show inhibitory activity against another class of
metabolic proteins, carboxylesterases.25 N-Alkylated isatins
have recently been described as caspase-3 activity inhibitors.26
Isatin-benzothiazole Schiﬀ base derivatives have shown
anticancer activity in breast tumor cell lines.27
Here, we report the discovery of isatin Mannich and Schiﬀ
base derivatives (IMSBDs) that activate the p53 transcription
factor. These compounds were identiﬁed by in silico screening
(Table S2), and their activities were validated in cellulo using a
human bone osteosarcoma epithelial U2OS cell line, which
stably expressed a p53-driven enhanced green ﬂuorescent
protein (EGFP) reporter.
We have virtually screened the in-house library of 38,000
compounds available at the St. Petersburg Technological
Institute. Analysis of the aﬃnity data along with visual
inspection allowed us to identify a list of potential MDM2-
p53 PPI IMSBDs inhibitors. Because the identiﬁed IMSBDs
can exist in two isomeric states,28 they were treated as separate
E- and Z-isomers. Some of the IMSBDs were poorly soluble,
whereas others had low inhibitory activity and high cytotoxicity
levels (only the N-substituted benzamide isatin Schiﬀ base
derivatives showed signiﬁcant p53 activation levels (Table 1)
accompanied by low toxicity).
The identiﬁed compounds represent a combination of
Mannich29 and Schiﬀ bases that are known to have a tendency
for hydrolysis. Therefore, we separately analyzed two diﬀerent
possible hydrolysis reactions (Figure S7) of IMSBD4 using
UV−vis spectrometry. As seen in Figure S6, incubation of the
isatin Mannich base for 12 h at pH 7.5 and 37 °C led to its
almost complete hydrolysis. In contrast, the isatin Schiﬀ base
exhibited a much lower rate of hydrolysis. Thus, we predicted
that even though the selected compounds undergo hydrolysis,
they still exert their biological functions as non-N-substituted
Schiﬀ bases.
Importantly, we found that the compounds bind with BSA,
which is abundantly present in serum. The interaction of
compounds with both BSA and MDM2 might also prevent
these compounds from undergoing hydrolysis. For instance,
Kimble-Hill et al.24 reported successful crystallization of the
nonhydrolyzed Mannich base (N-[(1-piperazinyl)methyl]-
isatin) with the ALDH3A1 protein using the same pH and
buﬀer system in the crystallization assay as we used in our
hydrolysis studies. Thus, the larger peak shifts in the UV−vis
spectra in the culture media than in the buﬀer (Figure S6) can
be explained by the eﬀect of BSA binding.
We analyzed the ability of both ISBD isomers to dock to the
p53-binding pocket of MDM2. The (E)-ISBDs docked to the
p53-binding pocket with lower ΔG than the Z-form by
approximately 1 kcal/mol. As seen in Figure 1, the (E)-ISBD2
isomer forms mainly hydrophobic interactions with the MDM2
p53-binding site (Leu pocket, π−π stacking interaction with
His96 and Tyr100). The calculated aﬃnity of (S,E)-ISBD1 to
the p53-binding pocket of MDM2 is one-fold lower in Ki units
than the corresponding value for ISBD2. We propose that the
identiﬁed ISBDs can act as a p53 α-helix mimetic (Figure 1),
whereby the phenyl ring of ISBD2 overlays the Phe19 residue,
and the isatin core overlays the hydrophobic Leu26 of the p53
α-helix. Furthermore, the methylated aliphatic carbon in (S,E)-
ISBD1 alters the conformation of the ligand, causing the phenyl
ring to overlay the Trp23 residue.
One of the major limitations of p53-activating ISBDs is the
presence of E-to-Z interconversion, which lowers the overall
binding aﬃnity to MDM2. As previously reported,28 ISBDs
crystallize preferentially in the (E)-conformation but convert to
the (Z)-form when dissolved. The topology of the (Z)-form
Table 1. EGFP Activation and Cytotoxicity after Treatment
with IMSBDs
number of cells
EGFP total
IMSBDs R1, R2 IMSBDs/Nutlin p53
+ p53−
1 Bn-piperazine, Me 8.70 0.04 0.27
2 Bn-piperidine, H 4.90 0.14 0.32
3 Bn-piperazine, H 4.20 0.10 0.19
4 Ph-piperazine, H 3.90 0.22 0.40
5 2-F-Ph-piperazine, H 3.60 0.11 0.24
6 methylbenzylamine, H 3.10 0.14 0.41
Figure 1. Superimposed representation of the docked poses of ISBD2
(blue) and ISBD1 (rose) with the p53 TAD1 α-helix (cyan).
ACS Medicinal Chemistry Letters Letter
DOI: 10.1021/acsmedchemlett.5b00011
ACS Med. Chem. Lett. 2015, 6, 856−860
857
D
ow
nl
oa
de
d 
by
 S
T 
PE
TE
RS
BU
RG
 S
TA
TE
 U
N
IV
 o
n 
A
ug
us
t 2
5,
 2
01
5 
| ht
tp:
//p
ubs
.ac
s.o
rg 
 
Pu
bl
ic
at
io
n 
D
at
e 
(W
eb
): 
Ju
ly 
9, 
20
15
 | d
oi:
 10
.10
21/
acs
me
dch
em
lett
.5b
000
11
diﬀers substantially from that of the (E)-conformer (Figure
S10).
We performed 2D NMR experiments on IMSBD4 to obtain
the relationship of E-to-Z solution concentrations. The spectral
data (Supporting Information) conﬁrm the molar (E-to-Z)
ratio to be 8:1 in polar DMSO (ε = 46.8) and in less polar
chloroform (ε = 4.7). We suggest that the ratio between these
isomers remains approximately the same when dissolved in
culture medium for in vivo studies. We also conﬁrmed the
presence of the E-conﬁguration in the solid state by solving the
crystal structure of IMSBD4 (Table S1 and Figure S2).
To validate our in silico predictions, we decided to study the
eﬀect of SMs on p53 stabilization and activation. To this end,
we developed a cell-based reporter system using the p53-
positive U2OS cell line (Figure 2).
Unlike in vitro models, this approach is less prone to false-
positive signals due to the lower background of oﬀ-target
eﬀects. The resulting cell line features an episomal plasmid that
contains the EGFP coding sequence under the control of ﬁve
repeated p53 response elements taken from the promoter
region of the p21 gene, which is the bona f ide target of p53
transcriptional activity.
Upon treatment with activating SMs (e.g., MDM2-p53 PPI
inhibitors), cellular p53 is stabilized by the acetylation
modiﬁcation.30 Subsequently, p53 binds the response elements
and triggers transcription of the EGFP gene, whose product
emits ﬂuorescence. Therefore, the eﬃcacy of p53-activating
SMs was measured indirectly as the number of EGFP-positive
cells.
As shown in Figure 3, the presence of EGFP-positive cells
(green) demonstrates that IMSBD4 activates p53-dependent
transcription of the EGFP reporter.
Quantitatively, the potency of compounds was estimated as
the ratio between the percentage of EGFP-positive cells after
treatment with IMSBDs (2.5 μM, 48 h) and the eﬀect of a well-
characterized nongenotoxic MDM2 inhibitor, Nutlin-3. N-
Mannich bases of ISBDs substituted with N-(benzyl)benzamide
demonstrated higher levels of p53 activation than the control
Nutlin-3 inhibitor (Table 1). EGFP activation and cytotoxicity
(Hoechst stain) values in p53+ and p53− cells treated with
various IMSBDs are shown as ratios between the eﬀects of
compounds and the eﬀects mediated by Nutlin-3 treatment,
which were arbitrarily set as 1.
As seen in Table 1, diﬀerent IMSBDs activate p53 in U2OS-
pLV cells (as measured by the number of cells “with EGFP”) at
various levels but are consistently more eﬀective than Nutlin-3.
We also measured the cytotoxic eﬀect of SMs by counting the
number of cells that survived after the treatment. The
cytotoxicity of IMSBDs was clearly and consistently higher in
p53+ cells versus p53− cells (Table 1, compare the last two
rows), which indicates that these eﬀects are p53 dependent.
The fact that IMSBD cytotoxicity was higher than that of
Nutlin-3 suggests that these compounds may have additional
targets and/or activate the apoptotic p53 pathway, which is
mechanistically diﬀerent from the pathway activated by Nutlin-
3 in these cells.
The diﬀerence in activity between IMSBD2−IMSBD6 is not
signiﬁcant (compared to IMSBD1), which supports the
hypothesis that the common Schiﬀ base is the active part of
IMSBDs and that the variable Mannich base has no signiﬁcant
eﬀect on the activity of SMs. Slight diﬀerences in the activity
can be explained by the diﬀerences in physical properties (e.g.,
logP and PSA) of IMSBDs, whereas the binding poses of ISBD
and IMSBD to MDM2 are generally similar (Figure S9).
To directly assess the eﬀect of IMSBDs on the stability of the
p53 protein, we performed Western blotting (WB), which
allows measurement of the intracellular levels of the p53
protein. The representative WB data using IMSBD4 are shown
in Figure 4. Treatment of U2OS-pLV cells with IMSBD4 for 12
h resulted in p53 stabilization comparable to the eﬀect of
Nutlin-3 but was less pronounced than Doxorubicin (DOXO).
We also examined the levels of MDM2 expression as it is the
transcriptional target of p53, and the MDM2 gene product
ubiquitinates p53.31 As shown in Figure 4, although IMSBD4
does signiﬁcantly increase the level of p53, it has little or no
inﬂuence on the protein level of MDM2. In contrast, Nutlin-3
and Doxorubicin increased the level of MDM2 in U2OS-pLV
cells. This discrepancy also indicates that IMSBDs may stabilize
Figure 2. Schematic representation of the test-system containing ﬁve
p53 response elements.
Figure 3. Representative image of the U2OS-pLV cell line response to
treatment with Nutlin-3 (2.5 μM) (A) and IMSBD4 (2.5 μM) (B).
Figure 4. WB analysis of the p53 protein levels after treatment with
diﬀerent compounds.
ACS Medicinal Chemistry Letters Letter
DOI: 10.1021/acsmedchemlett.5b00011
ACS Med. Chem. Lett. 2015, 6, 856−860
858
D
ow
nl
oa
de
d 
by
 S
T 
PE
TE
RS
BU
RG
 S
TA
TE
 U
N
IV
 o
n 
A
ug
us
t 2
5,
 2
01
5 
| ht
tp:
//p
ubs
.ac
s.o
rg 
 
Pu
bl
ic
at
io
n 
D
at
e 
(W
eb
): 
Ju
ly 
9, 
20
15
 | d
oi:
 10
.10
21/
acs
me
dch
em
lett
.5b
000
11
p53 by a diﬀerent mechanism(s) from the one exerted by
Nutlin-3. For instance, a close ISBD analogue, 4-hydroxyben-
zylideneindolin-2-one, has been reported as a micromolar
inhibitor of Polo-like kinase 4, which is indirectly involved in
the regulation of p53.32 However, the exact molecular
mechanism of p53 stabilization requires additional investiga-
tion.
Using in silico and in vivo studies, we have identiﬁed several
isatin-based derivatives that display strong p53 stimulatory
eﬀects. Based on in silico modeling, we assume that these novel
pharmacological activators of p53 may disrupt the PPI between
p53 and MDM2. However, further studies are required to
establish the precise molecular mechanism of this phenomenon.
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